Royal Commission for AlUla, SETI Institute Collaborate to Develop AlUla Manara Observatory

The Royal Commission for AlUla logo
The Royal Commission for AlUla logo
TT

Royal Commission for AlUla, SETI Institute Collaborate to Develop AlUla Manara Observatory

The Royal Commission for AlUla logo
The Royal Commission for AlUla logo

The Royal Commission for AlUla has signed a cooperation agreement with SETI Institute to support the development of the AlUla Manara Observatory, which will act as a leading global center for innovation and excellence in space and astronomy sciences.

The agreement seeks to boost AlUla's status as a leading world destination for star and astronomy exploration tourism.

The collaboration will make AlUla Manara a hub for scientific advancement through joint research projects and initiatives for the growing astro-tourism sector in AlUla, and will provide educational opportunities to develop skills needed to work at the observatory, including supporting research and development programs with the latest systems and equipment. These advancements will enable scientists to conduct comprehensive space surveys and analyze data to identify new stars, planets, and comets.

Supervisor of the AlUla Manara program Eng. Nayef Al-Malik said that the collaboration strengthens AlUla’s role as a vital center for the exchange of science and knowledge.

He said that SETI Institute is one of the world’s leading organizations in research and scientific exploration, equipped with decades of technical expertise and knowledge in space and astronomy.

Al-Malik pointed out that the institute will support the development of data analysis systems for a range of telescopes planned for the observatory.

The observatory's educational centers will enhance local capabilities in space sciences using virtual reality. Furthermore, the awareness center will offer visitors to the observatory the chance to get familiarized with astronomy, in line with the commission’s vision to establish AlUla as a knowledge-sharing global center for research, innovation.

SETI Institute CEO Bill Diamond stressed that the institute’s mission is to share the results of its research with the world, noting that the collaboration with the Royal Commission for AlUla opens new horizons for advancing space sciences, education, and technology development.

"We envision the AlUla Manara Observatory as a beacon of discovery, equipped with advanced and modern telescopes to detect new planets and stars, pushing astronomical research to further frontiers,” Senior Planetary Astronomer and Director of Citizen Science at the institute Frank Marchis said.

He also said that their initiative in astronomical sciences will invite the community and tourists to “stargaze, explore AlUla’s rich scientific heritage, foster international collaboration, and revive humanity's deep connection with the universe.”

The AlUla Manara Observatory is set to open in several phases over the coming years, and carry out continuous research, collaboration, and educational initiatives.

AlUla Manara Observatory, currently under development, is located near the Gharameel area, in AlUla, which is one of the top 10% global locations with clear, dark skies.



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.